Observational studyEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2026
Impact of Surgical Intervention in Patients With Macrolide-Resistant Mycobacterium avium Complex Pulmonary Disease: A Multicentre Study.
Observational study in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTreatment for patients with macrolide-resistant Mycobacterium avium complex (MR-MAC) pulmonary disease is a major clinical challenge, as pharmacologic options are limited and outcomes with antibiotics alone are unsatisfactory. Although surgical intervention has been considered in selected cases, clinical evidence specific to MR-MAC is limited. This study aimed to compare the clinical outcomes of surgical intervention for MR-MAC pulmonary disease to those of non-resistant cases.
methodsThis multicentre study included 248 patients who underwent pulmonary resection for MAC pulmonary disease. Among them, 34 patients (13.7%) had MR-MAC, which was defined as isolates with a clarithromycin minimum inhibitory concentration of ≥32 mg/L. Clinical outcomes were compared between the MR-MAC and non-MR-MAC groups. A multivariable analysis was conducted to identify risk factors for infectious relapse.
resultsIn the MR-MAC and non-MR-MAC groups, the 5-year overall survival, 5-year relapse-free survival and postoperative complication rates were 100% and 98.5%, 85.4% and 67.9%, and 8.8% and 11.9%, respectively (P = .72, .47, and .78, respectively). Multivariable analysis revealed older age and lack of amikacin use as independent risk factors for infectious relapse, but not macrolide resistance.
conclusionsSurgical resection is a viable and safe therapeutic option for selected patients with MR-MAC pulmonary disease, with long-term infection control comparable to that of non-MR-MAC cases. These findings support early surgical intervention in carefully selected patients with localized destructive lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.